Skip to content

Tuesday, April 23, 2024

Latest:

Your foot hurts. What do you do now?
When medicine becomes political
Cancer-predisposition variants associated with adverse outcomes in rhabdomyosarcoma
Collaborating with the community for autism research
Virtual education programs train clinicians around the world

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

MAPK inhibitor

A promising two-punch therapy for Langerhans cell histiocytosis

June 29, 2021 dendritic cells, Langerhans cell histiocytosis, MAPK inhibitor, PD-1 receptors, rare cancer, Research, T-cell exhaustion

A novel combination therapy resulted in a significant decrease of disease burden in an animal model of LCH.

From the Labs Image of the Month:

From the Labs: Human retinal organoid.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951